Universal Beteiligungs und Servicegesellschaft mbH Buys 39,326 Shares of Exelixis, Inc. $EXEL

Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 8.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 496,791 shares of the biotechnology company’s stock after buying an additional 39,326 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of Exelixis worth $20,517,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in Exelixis by 10.3% in the 2nd quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after acquiring an additional 712,190 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Exelixis by 0.4% during the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after purchasing an additional 28,289 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of Exelixis by 42.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after purchasing an additional 1,580,567 shares during the period. Qube Research & Technologies Ltd raised its stake in shares of Exelixis by 120.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after purchasing an additional 1,665,110 shares in the last quarter. Finally, Norges Bank bought a new position in Exelixis in the second quarter worth $122,099,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wolfe Research began coverage on shares of Exelixis in a research note on Tuesday, November 18th. They issued a “peer perform” rating for the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $45.00 price target on shares of Exelixis in a research report on Tuesday, October 21st. HC Wainwright raised their price target on shares of Exelixis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wells Fargo & Company lowered their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 21st. Finally, UBS Group set a $41.00 target price on Exelixis in a report on Monday, January 5th. Eleven analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $45.95.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 28,043 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the completion of the sale, the executive vice president owned 374,029 shares of the company’s stock, valued at $15,926,154.82. This trade represents a 6.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Dana Aftab sold 48,383 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the completion of the transaction, the executive vice president owned 664,778 shares of the company’s stock, valued at $28,253,065. This trade represents a 6.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 245,235 shares of company stock worth $10,490,600 in the last quarter. Insiders own 2.82% of the company’s stock.

Exelixis Price Performance

Shares of EXEL opened at $44.50 on Friday. The company has a market capitalization of $11.93 billion, a P/E ratio of 18.78, a PEG ratio of 0.81 and a beta of 0.40. Exelixis, Inc. has a one year low of $31.90 and a one year high of $49.62. The business’s 50 day simple moving average is $43.66 and its 200-day simple moving average is $41.12.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS. On average, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.